HLA-A02:01-restricted epitopes identified from the herpes simplex virus tegument protein VP11/12 preferentially recall polyfunctional effector memory CD8+ T cells from seropositive asymptomatic individuals and protect humanized HLA-A02:01 transgenic mice against ocular herpes

The HSV type 1 tegument virion phosphoprotein (VP) 11/12 (VP11/12) is a major Ag targeted by CD8(+) T cells from HSV-seropositive individuals. However, whether and which VP11/12 epitope-specific CD8(+) T cells play a role in the "natural" protection seen in seropositive healthy asymptomati...

Full description

Saved in:
Bibliographic Details
Published inThe Journal of immunology (1950) Vol. 194; no. 5; pp. 2232 - 2248
Main Authors Srivastava, Ruchi, Khan, Arif A, Spencer, Doran, Vahed, Hawa, Lopes, Patricia P, Thai, Nhi Thi Uyen, Wang, Christine, Pham, Thanh T, Huang, Jiawei, Scarfone, Vanessa M, Nesburn, Anthony B, Wechsler, Steven L, BenMohamed, Lbachir
Format Journal Article
LanguageEnglish
Published United States 01.03.2015
Subjects
Adolescent
Adult
Aged
Algorithms
Amino Acid Sequence
Animals
Antigens, Viral - chemistry
Antigens, Viral - immunology
Asymptomatic Diseases
CD8-Positive T-Lymphocytes - immunology
CD8-Positive T-Lymphocytes - pathology
CD8-Positive T-Lymphocytes - virology
Epitopes, T-Lymphocyte - chemistry
Epitopes, T-Lymphocyte - immunology
Female
Herpes simplex virus
Herpesvirus 1, Human - chemistry
Herpesvirus 1, Human - immunology
Herpesvirus 2, Human - chemistry
Herpesvirus 2, Human - immunology
HLA-A2 Antigen - chemistry
HLA-A2 Antigen - immunology
Humans
Immunity, Cellular
Immunization
Immunologic Memory
Keratitis, Herpetic - immunology
Keratitis, Herpetic - pathology
Keratitis, Herpetic - prevention & control
Keratitis, Herpetic - virology
Male
Mice
Mice, Transgenic
Middle Aged
Molecular Sequence Data
Peptides - administration & dosage
Peptides - chemistry
Peptides - immunology
Viral Proteins - chemistry
Viral Proteins - immunology
Online AccessGet full text

Cover

Abstract The HSV type 1 tegument virion phosphoprotein (VP) 11/12 (VP11/12) is a major Ag targeted by CD8(+) T cells from HSV-seropositive individuals. However, whether and which VP11/12 epitope-specific CD8(+) T cells play a role in the "natural" protection seen in seropositive healthy asymptomatic (ASYMP) individuals (who have never had clinical herpes disease) remain to be determined. In this study, we used multiple prediction computer-assisted algorithms to identify 10 potential HLA-A*02:01-restricted CD8(+) T cell epitopes from the 718-aa sequence of VP11/12. Three of 10 epitopes exhibited high-to-moderate binding affinity to HLA-A*02:01 molecules. In 10 sequentially studied HLA-A*02:01-positive and HSV-1-seropositive ASYMP individuals, the most frequent, robust, and polyfunctional effector CD8(+) T cell responses, as assessed by a combination of tetramer frequency, granzyme B, granzyme K, perforin, CD107(a/b) cytotoxic degranulation, IFN-γ, and multiplex cytokines assays, were predominantly directed against three epitopes: VP11/1266-74, VP11/12220-228, and VP11/12702-710. Interestingly, ASYMP individuals had a significantly higher proportion of CD45RA(low)CCR7(low)CD44(high)CD62L(low)CD27(low)CD28(low)CD8(+) effector memory CD8(+) T cells (TEMs) specific to the three epitopes, compared with symptomatic individuals (with a history of numerous episodes of recurrent ocular herpetic disease). Moreover, immunization of HLA-A*02:01 transgenic mice with the three ASYMP CD8(+) TEM cell epitopes induced robust and polyfunctional epitope-specific CD8(+) TEM cells that were associated with a strong protective immunity against ocular herpes infection and disease. Our findings outline phenotypic and functional features of protective HSV-specific CD8(+) T cells that should guide the development of an effective T cell-based herpes vaccine.
AbstractList The HSV type 1 tegument virion phosphoprotein (VP) 11/12 (VP11/12) is a major Ag targeted by CD8+ T cells from HSV-seropositive individuals. However, whether and which VP11/12 epitope-specific CD8+ T cells play a role in the "natural" protection seen in seropositive healthy asymptomatic (ASYMP) individuals (who have never had clinical herpes disease) remain to be determined. In this study, we used multiple prediction computer-assisted algorithms to identify 10 potential HLA-A*02:01-restricted CD8+ T cell epitopes from the 718-aa sequence of VP11/12. Three of 10 epitopes exhibited high-to-moderate binding affinity to HLA-A*02:01 molecules. In 10 sequentially studied HLA-A*02:01-positive and HSV-1-seropositive ASYMP individuals, the most frequent, robust, and polyfunctional effector CD8+ T cell responses, as assessed by a combination of tetramer frequency, granzyme B, granzyme K, perforin, CD107a/b cytotoxic degranulation, IFN- gamma , and multiplex cytokines assays, were predominantly directed against three epitopes: VP11/1266-74, VP11/12220-228, and VP11/12702-710. Interestingly, ASYMP individuals had a significantly higher proportion of CD45RAlowCCR7lowCD44highCD62LlowCD27lowCD28lowCD8+ effector memory CD8+ T cells (TEMs) specific to the three epitopes, compared with symptomatic individuals (with a history of numerous episodes of recurrent ocular herpetic disease). Moreover, immunization of HLA-A*02:01 transgenic mice with the three ASYMP CD8+ TEM cell epitopes induced robust and polyfunctional epitope-specific CD8+ TEM cells that were associated with a strong protective immunity against ocular herpes infection and disease. Our findings outline phenotypic and functional features of protective HSV-specific CD8+ T cells that should guide the development of an effective T cell-based herpes vaccine.
The HSV type 1 tegument virion phosphoprotein (VP) 11/12 (VP11/12) is a major Ag targeted by CD8+ T cells from HSV-seropositive individuals. However, whether and which VP11/12 epitope–specific CD8+ T cells play a role in the “natural” protection seen in seropositive healthy asymptomatic (ASYMP) individuals (who have never had clinical herpes disease) remain to be determined. In this study, we used multiple prediction computer-assisted algorithms to identify 10 potential HLA-A*02:01–restricted CD8+ T cell epitopes from the 718-aa sequence of VP11/12. Three of 10 epitopes exhibited high-to-moderate binding affinity to HLA-A*02:01 molecules. In 10 sequentially studied HLA-A*02:01–positive and HSV-1–seropositive ASYMP individuals, the most frequent, robust, and polyfunctional effector CD8+ T cell responses, as assessed by a combination of tetramer frequency, granzyme B, granzyme K, perforin, CD107a/b cytotoxic degranulation, IFN-γ, and multiplex cytokines assays, were predominantly directed against three epitopes: VP11/1266–74, VP11/12220–228, and VP11/12702–710. Interestingly, ASYMP individuals had a significantly higher proportion of CD45RAlowCCR7lowCD44highCD62LlowCD27lowCD28lowCD8+ effector memory CD8+ T cells (TEMs) specific to the three epitopes, compared with symptomatic individuals (with a history of numerous episodes of recurrent ocular herpetic disease). Moreover, immunization of HLA-A*02:01 transgenic mice with the three ASYMP CD8+ TEM cell epitopes induced robust and polyfunctional epitope-specific CD8+ TEM cells that were associated with a strong protective immunity against ocular herpes infection and disease. Our findings outline phenotypic and functional features of protective HSV-specific CD8+ T cells that should guide the development of an effective T cell–based herpes vaccine.
The Herpes Simplex Virus type 1 virion tegument phosphoprotein 11/12 (HSV-1 VP11/12) is a major antigen targeted by CD8 + T cells from HSV-seropositive individuals. However, whether and which VP11/12-epitope-specific CD8 + T cells play a role in the “natural” protection seen in seropositive healthy asymptomatic (ASYMP) individuals (who have never had clinical herpes disease) remain to be determined. In this study, we used multiple prediction computer-assisted algorithms to identify 10 potential HLA-A*02:01-restricted CD8 + T cell epitopes from the 716 amino acids sequence of VP11/12. Three out of ten epitopes exhibited high to moderate binding affinity to HLA-A*02:01 molecules. In ten sequentially studied HLA-A*02:01 positive and HSV-1-seropositive ASYMP individuals, the most frequent, robust and polyfunctional effector CD8 + T-cell responses, as assessed by a combination of tetramer frequency, granzyme B, granzyme K, perforin, CD107 a/b cytotoxic degranulation, IFN-γ and multiplex cytokines assays, were predominantly directed against three epitopes: VP11/12 66–74 , VP11/12 220–228 and VP11/12 702–710 . Interestingly, ASYMP individuals had significantly higher proportion of CD45RA low CCR7 low CD44 high CD62L low CD27 low CD28 low CD8 + effector memory T cells (T EM ) specific to the three epitopes, compared to symptomatic (SYMP) individuals (with a history of numerous episodes of recurrent ocular herpetic disease). Moreover, immunization of HLA-A*02:01 transgenic mice with the three ASYMP CD8 + T EM cell epitopes induced robust and polyfunctional epitope-specific CD8 + T EM cells that were associated with a strong protective immunity against ocular herpes infection and disease. Our findings outline phenotypic and functional features of protective HSV-specific CD8 + T cells that should guide the development of an effective T-cell-based herpes vaccine.
The HSV type 1 tegument virion phosphoprotein (VP) 11/12 (VP11/12) is a major Ag targeted by CD8(+) T cells from HSV-seropositive individuals. However, whether and which VP11/12 epitope-specific CD8(+) T cells play a role in the "natural" protection seen in seropositive healthy asymptomatic (ASYMP) individuals (who have never had clinical herpes disease) remain to be determined. In this study, we used multiple prediction computer-assisted algorithms to identify 10 potential HLA-A*02:01-restricted CD8(+) T cell epitopes from the 718-aa sequence of VP11/12. Three of 10 epitopes exhibited high-to-moderate binding affinity to HLA-A*02:01 molecules. In 10 sequentially studied HLA-A*02:01-positive and HSV-1-seropositive ASYMP individuals, the most frequent, robust, and polyfunctional effector CD8(+) T cell responses, as assessed by a combination of tetramer frequency, granzyme B, granzyme K, perforin, CD107(a/b) cytotoxic degranulation, IFN-γ, and multiplex cytokines assays, were predominantly directed against three epitopes: VP11/1266-74, VP11/12220-228, and VP11/12702-710. Interestingly, ASYMP individuals had a significantly higher proportion of CD45RA(low)CCR7(low)CD44(high)CD62L(low)CD27(low)CD28(low)CD8(+) effector memory CD8(+) T cells (TEMs) specific to the three epitopes, compared with symptomatic individuals (with a history of numerous episodes of recurrent ocular herpetic disease). Moreover, immunization of HLA-A*02:01 transgenic mice with the three ASYMP CD8(+) TEM cell epitopes induced robust and polyfunctional epitope-specific CD8(+) TEM cells that were associated with a strong protective immunity against ocular herpes infection and disease. Our findings outline phenotypic and functional features of protective HSV-specific CD8(+) T cells that should guide the development of an effective T cell-based herpes vaccine.
Author Khan, Arif A
Pham, Thanh T
Thai, Nhi Thi Uyen
Vahed, Hawa
Scarfone, Vanessa M
Lopes, Patricia P
Wechsler, Steven L
Wang, Christine
Spencer, Doran
BenMohamed, Lbachir
Srivastava, Ruchi
Huang, Jiawei
Nesburn, Anthony B
AuthorAffiliation 2 Stem Cell Research Center, University of California Irvine, Irvine, CA 92697
6 Department of Molecular Biology & Biochemistry, University of California Irvine, School of Medicine, Irvine, CA 92697
7 Institute for Immunology; University of California Irvine, School of Medicine, Irvine, CA 92697
4 Department of Microbiology and Molecular Genetics, University of California Irvine, School of Medicine, Irvine, California 92697
5 Center for Virus Research, University of California Irvine, Irvine, California 92697
1 Laboratory of Cellular and Molecular Immunology, Gavin Herbert Eye Institute, University of California Irvine, School of Medicine, Irvine, CA 92697
3 Virology Research, Gavin Herbert Eye Institute and Department of Ophthalmology, University of California Irvine, School of Medicine, Irvine, California 92697
AuthorAffiliation_xml – name: 4 Department of Microbiology and Molecular Genetics, University of California Irvine, School of Medicine, Irvine, California 92697
– name: 1 Laboratory of Cellular and Molecular Immunology, Gavin Herbert Eye Institute, University of California Irvine, School of Medicine, Irvine, CA 92697
– name: 6 Department of Molecular Biology & Biochemistry, University of California Irvine, School of Medicine, Irvine, CA 92697
– name: 2 Stem Cell Research Center, University of California Irvine, Irvine, CA 92697
– name: 5 Center for Virus Research, University of California Irvine, Irvine, California 92697
– name: 7 Institute for Immunology; University of California Irvine, School of Medicine, Irvine, CA 92697
– name: 3 Virology Research, Gavin Herbert Eye Institute and Department of Ophthalmology, University of California Irvine, School of Medicine, Irvine, California 92697
Author_xml – sequence: 1
  givenname: Ruchi
  surname: Srivastava
  fullname: Srivastava, Ruchi
  organization: Laboratory of Cellular and Molecular Immunology, Gavin Herbert Eye Institute, University of California Irvine, School of Medicine, Irvine, CA 92697
– sequence: 2
  givenname: Arif A
  surname: Khan
  fullname: Khan, Arif A
  organization: Laboratory of Cellular and Molecular Immunology, Gavin Herbert Eye Institute, University of California Irvine, School of Medicine, Irvine, CA 92697
– sequence: 3
  givenname: Doran
  surname: Spencer
  fullname: Spencer, Doran
  organization: Laboratory of Cellular and Molecular Immunology, Gavin Herbert Eye Institute, University of California Irvine, School of Medicine, Irvine, CA 92697
– sequence: 4
  givenname: Hawa
  surname: Vahed
  fullname: Vahed, Hawa
  organization: Laboratory of Cellular and Molecular Immunology, Gavin Herbert Eye Institute, University of California Irvine, School of Medicine, Irvine, CA 92697
– sequence: 5
  givenname: Patricia P
  surname: Lopes
  fullname: Lopes, Patricia P
  organization: Laboratory of Cellular and Molecular Immunology, Gavin Herbert Eye Institute, University of California Irvine, School of Medicine, Irvine, CA 92697
– sequence: 6
  givenname: Nhi Thi Uyen
  surname: Thai
  fullname: Thai, Nhi Thi Uyen
  organization: Laboratory of Cellular and Molecular Immunology, Gavin Herbert Eye Institute, University of California Irvine, School of Medicine, Irvine, CA 92697
– sequence: 7
  givenname: Christine
  surname: Wang
  fullname: Wang, Christine
  organization: Laboratory of Cellular and Molecular Immunology, Gavin Herbert Eye Institute, University of California Irvine, School of Medicine, Irvine, CA 92697
– sequence: 8
  givenname: Thanh T
  surname: Pham
  fullname: Pham, Thanh T
  organization: Laboratory of Cellular and Molecular Immunology, Gavin Herbert Eye Institute, University of California Irvine, School of Medicine, Irvine, CA 92697
– sequence: 9
  givenname: Jiawei
  surname: Huang
  fullname: Huang, Jiawei
  organization: Laboratory of Cellular and Molecular Immunology, Gavin Herbert Eye Institute, University of California Irvine, School of Medicine, Irvine, CA 92697
– sequence: 10
  givenname: Vanessa M
  surname: Scarfone
  fullname: Scarfone, Vanessa M
  organization: Stem Cell Research Center, University of California Irvine, Irvine, CA 92697
– sequence: 11
  givenname: Anthony B
  surname: Nesburn
  fullname: Nesburn, Anthony B
  organization: Laboratory of Cellular and Molecular Immunology, Gavin Herbert Eye Institute, University of California Irvine, School of Medicine, Irvine, CA 92697
– sequence: 12
  givenname: Steven L
  surname: Wechsler
  fullname: Wechsler, Steven L
  organization: Laboratory of Cellular and Molecular Immunology, Gavin Herbert Eye Institute, University of California Irvine, School of Medicine, Irvine, CA 92697; Virology Research, Gavin Herbert Eye Institute and Department of Ophthalmology, University of California Irvine, School of Medicine, Irvine, CA 92697; Department of Microbiology and Molecular Genetics, University of California Irvine, School of Medicine, Irvine, CA 92697; Center for Virus Research, University of California Irvine, Irvine, CA 92697
– sequence: 13
  givenname: Lbachir
  surname: BenMohamed
  fullname: BenMohamed, Lbachir
  email: Lbenmoha@uci.edu
  organization: Laboratory of Cellular and Molecular Immunology, Gavin Herbert Eye Institute, University of California Irvine, School of Medicine, Irvine, CA 92697; Department of Molecular Biology and Biochemistry, University of California Irvine, School of Medicine, Irvine, CA 92697; and Institute for Immunology, University of California Irvine, School of Medicine, Irvine, CA 92697 Lbenmoha@uci.edu
BackLink https://www.ncbi.nlm.nih.gov/pubmed/25617474$$D View this record in MEDLINE/PubMed
BookMark eNqFUkuP0zAQDmgR2124ceCEfERC2bUTOw8OSFV5LFIlOCxcI9cZt7OK7WA7FeHX46rdBU5cPB7PN5_n8V1kZ9ZZyLKXjF5xytvrOzRmsm64YpwWFa0eZwsmBM2rdD_LFpQWRc7qqj7PLkK4o5RWtOBPs_NCVKzmNV88enGzXuZLWrylLPcQokcVoScwYnQjBII92Iga05v2zpC4A7IDfwgFNOMAP8ke_RRIhO1kEpaM3kVAS75_ZeyaFckHDf7AIodhJh5UsmR0w6wnqyI6KwcCWoOKzhMDxvmZrN43b8gtUTAM4fhxAO9GFzDiHogMsxmjMzKiImh73GM_yQSVtj8WoCLZTUZa_JUq_9MjiV7asAWb8gyqxLSVaEMkTk2D9KfWnmVPdGKD5yd7mX37-OF2dZOvv3z6vFquc1WKNuYaSqlhI0CLgjFZaKWEEL0QNS9ZyyrayrZphS7pplabnstSFk2_kWlFLbRclJfZuyPvOG0M9CoNycuhGz0a6efOSez-jVjcdVu373jJaV2VieD1icC7H1NaX2cwHIYmLbgpdKyhTZWOtvk_tBJNTcumbhOUHqHKuxDS-h4qYrQ76K6711130l1KefV3Jw8J90IrfwOnYN5R
CitedBy_id crossref_primary_10_1128_JVI_01000_20
crossref_primary_10_1128_JVI_00788_15
crossref_primary_10_1007_s00251_022_01288_z
crossref_primary_10_3389_fimmu_2016_00298
crossref_primary_10_1128_JVI_03419_14
crossref_primary_10_1038_s41598_020_70673_z
crossref_primary_10_1128_JVI_00278_17
crossref_primary_10_1016_j_vaccine_2016_03_022
crossref_primary_10_1128_JVI_00810_17
crossref_primary_10_1128_JVI_00535_18
crossref_primary_10_1128_JVI_01882_18
crossref_primary_10_1007_s40588_015_0020_4
crossref_primary_10_4049_jimmunol_2000131
crossref_primary_10_3109_02713683_2015_1061024
crossref_primary_10_1001_jama_2022_19061
crossref_primary_10_1038_gene_2016_42
crossref_primary_10_1155_2016_2460184
crossref_primary_10_1002_rmv_2054
crossref_primary_10_1097_INF_0000000000001631
crossref_primary_10_1155_2017_9163719
crossref_primary_10_1128_JVI_02450_15
crossref_primary_10_4049_jimmunol_1800725
crossref_primary_10_3389_fimmu_2018_02922
crossref_primary_10_4049_jimmunol_1700145
crossref_primary_10_3390_ijms20246337
crossref_primary_10_1016_j_vaccine_2021_03_075
crossref_primary_10_3390_pathogens10111470
crossref_primary_10_4049_jimmunol_1502366
crossref_primary_10_3389_fmicb_2017_01958
crossref_primary_10_1128_JVI_00827_19
crossref_primary_10_1128_JVI_01793_16
crossref_primary_10_1007_s00705_021_05158_z
crossref_primary_10_3390_vaccines8020274
Cites_doi 10.2217/fvl.12.22
10.4049/jimmunol.0902168
10.1084/jem.20070841
10.1016/S0198-8859(01)00319-6
10.1016/j.humimm.2006.11.006
10.1084/jem.193.1.73
10.4049/jimmunol.166.6.4049
10.1002/eji.1830240341
10.1111/j.1440-1711.2006.01469.x
10.4049/jimmunol.156.8.2874
10.1111/j.0105-2896.2006.00394.x
10.1056/NEJMoa011915
10.1038/ni.2046
10.1046/j.1365-2567.2002.01396.x
10.1126/science.1159806
10.1016/j.humimm.2014.04.016
10.1128/JVI.79.24.15289-15301.2005
10.1182/blood.V99.9.3360
10.1038/44385
10.1016/j.vaccine.2011.06.083
10.1128/JVI.05194-11
10.4049/jimmunol.1301415
10.4049/jimmunol.1002042
10.1016/S1542-0124(12)70164-7
10.1128/JVI.73.9.7619-7626.1999
10.1128/JVI.07107-11
10.1038/81366
10.1016/j.virol.2014.07.018
10.1038/mi.2008.81
10.1158/0008-5472.CAN-03-2183
10.1172/JCI67388
10.1034/j.1399-0039.2002.590601.x
10.4049/jimmunol.173.3.1941
10.1128/JVI.00294-07
10.1056/NEJM199911043411904
10.1056/NEJMoa1103151
10.1167/iovs.08-2957
10.1073/pnas.1316178111
10.1016/j.virol.2008.03.018
10.1128/JVI.02464-08
10.1016/S0198-8859(00)00139-7
10.1016/j.vaccine.2014.10.002
10.1084/jem.20070322
10.1159/000348366
10.4049/jimmunol.1200063
10.4049/jimmunol.1300483
10.1002/eji.201141774
10.4049/jimmunol.1201121
10.1073/pnas.2131705100
10.1016/S1473-3099(02)00318-3
10.1016/S0022-1759(03)00265-5
10.4049/jimmunol.180.1.426
10.1590/S0100-879X2005000600004
10.1128/JVI.02659-05
10.1128/JVI.00692-08
10.4049/jimmunol.1003735
10.4049/jimmunol.0902322
10.1128/JVI.79.17.11523-11528.2005
10.4049/jimmunol.1002145
10.4049/jimmunol.172.11.6783
10.1167/iovs.07-0356
10.4049/jimmunol.180.12.7907
10.1002/1521-4141(200208)32:8<2274::AID-IMMU2274>3.0.CO;2-C
10.1016/j.smim.2004.08.014
10.4161/hv.27762
10.1002/eji.200425166
10.1093/Bioinformatics/btl324
10.1099/vir.0.008771-0
10.1016/S0264-410X(00)00068-2
10.1371/journal.pone.0039757
10.4049/jimmunol.177.11.7515
10.1128/JVI.00896-06
10.1038/nm942
10.4049/jimmunol.180.3.1309
ContentType Journal Article
Copyright Copyright © 2015 by The American Association of Immunologists, Inc.
Copyright_xml – notice: Copyright © 2015 by The American Association of Immunologists, Inc.
DBID CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
7X8
7QO
7T5
7U9
8FD
FR3
H94
P64
RC3
5PM
DOI 10.4049/jimmunol.1402606
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
CrossRef
MEDLINE - Academic
Biotechnology Research Abstracts
Immunology Abstracts
Virology and AIDS Abstracts
Technology Research Database
Engineering Research Database
AIDS and Cancer Research Abstracts
Biotechnology and BioEngineering Abstracts
Genetics Abstracts
PubMed Central (Full Participant titles)
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
CrossRef
MEDLINE - Academic
Genetics Abstracts
Virology and AIDS Abstracts
Biotechnology Research Abstracts
Technology Research Database
AIDS and Cancer Research Abstracts
Immunology Abstracts
Engineering Research Database
Biotechnology and BioEngineering Abstracts
DatabaseTitleList Genetics Abstracts
CrossRef

MEDLINE
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Biology
EISSN 1550-6606
EndPage 2248
ExternalDocumentID 10_4049_jimmunol_1402606
25617474
Genre Research Support, Non-U.S. Gov't
Journal Article
Research Support, N.I.H., Extramural
GrantInformation_xml – fundername: NEI NIH HHS
  grantid: EY14900
– fundername: NIAID NIH HHS
  grantid: 1R56AI098985
– fundername: NEI NIH HHS
  grantid: R01 EY024618
– fundername: NEI NIH HHS
  grantid: R01 EY013191
– fundername: NIAID NIH HHS
  grantid: R56 AI098985
– fundername: NIAID NIH HHS
  grantid: R56 AI093133
– fundername: NEI NIH HHS
  grantid: R01 EY019896
– fundername: NEI NIH HHS
  grantid: R01 EY014900
– fundername: NIAID NIH HHS
  grantid: 1R56AI093133
– fundername: NEI NIH HHS
  grantid: EY013191
GroupedDBID ---
-~X
.55
18M
2WC
34G
39C
53G
5GY
5RE
5VS
79B
85S
AARDX
ABCQX
ABJNI
ABOCM
ABPPZ
ACGFO
ACGFS
ACIWK
ACNCT
ACPRK
ADBBV
ADNWM
AENEX
AFHIN
AFOSN
AFRAH
AHWXS
AIZAD
ALMA_UNASSIGNED_HOLDINGS
BAWUL
BTFSW
CGR
CUY
CVF
D0L
DIK
DU5
E3Z
EBS
ECM
EIF
EJD
F5P
FRP
GX1
IH2
K-O
KQ8
L7B
NPM
OK1
P0W
P2P
PQQKQ
R.V
RHF
RHI
RZQ
SJN
TR2
TWZ
W8F
WH7
WOQ
X7M
XJT
XSW
XTH
YHG
5WD
AAYXX
CITATION
OCZFY
7X8
7QO
7T5
7U9
8FD
FR3
H94
P64
RC3
5PM
AETEA
ID FETCH-LOGICAL-c359t-fe3afeb5ef5211a2fcc555d55743191609a9895f30b7cbd4a3a28dba1559e9453
ISSN 0022-1767
IngestDate Tue Sep 17 21:17:05 EDT 2024
Wed Dec 04 10:38:16 EST 2024
Wed Dec 04 00:04:01 EST 2024
Fri Dec 06 01:27:11 EST 2024
Sat Sep 28 08:06:57 EDT 2024
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 5
Language English
License Copyright © 2015 by The American Association of Immunologists, Inc.
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c359t-fe3afeb5ef5211a2fcc555d55743191609a9895f30b7cbd4a3a28dba1559e9453
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
OpenAccessLink https://www.jimmunol.org/content/jimmunol/194/5/2232.full.pdf
PMID 25617474
PQID 1658703879
PQPubID 23479
PageCount 17
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_4340763
proquest_miscellaneous_1808618098
proquest_miscellaneous_1658703879
crossref_primary_10_4049_jimmunol_1402606
pubmed_primary_25617474
PublicationCentury 2000
PublicationDate 2015-03-01
PublicationDateYYYYMMDD 2015-03-01
PublicationDate_xml – month: 03
  year: 2015
  text: 2015-03-01
  day: 01
PublicationDecade 2010
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle The Journal of immunology (1950)
PublicationTitleAlternate J Immunol
PublicationYear 2015
References 22808056 - PLoS One. 2012;7(7):e39757
15528078 - Semin Immunol. 2004 Oct;16(5):335-47
11238653 - J Immunol. 2001 Mar 15;166(6):4049-58
12444179 - N Engl J Med. 2002 Nov 21;347(21):1652-61
11964304 - Blood. 2002 May 1;99(9):3360-6
24516158 - Proc Natl Acad Sci U S A. 2014 Feb 25;111(8):E784-93
21357536 - J Immunol. 2011 Apr 1;186(7):3927-33
12127354 - Lancet Infect Dis. 2002 Jul;2(7):425-31
24499824 - Hum Vaccin Immunother. 2014;10(4):945-63
25446827 - Vaccine. 2014 Nov 28;32(50):6733-45
24101547 - J Immunol. 2013 Nov 15;191(10):5124-38
14566059 - Proc Natl Acad Sci U S A. 2003 Oct 28;100(22):12899-904
17237084 - Bioinformatics. 2007 Jan 15;23(2):e148-55
15059918 - Cancer Res. 2004 Apr 1;64(7):2610-8
10438852 - J Virol. 1999 Sep;73(9):7619-26
12209640 - Eur J Immunol. 2002 Aug;32(8):2274-81
21623380 - Nat Immunol. 2011 Jul;12(7):663-71
20164414 - J Immunol. 2010 Mar 15;184(6):2825-38
15265928 - J Immunol. 2004 Aug 1;173(3):1941-50
19168902 - Invest Ophthalmol Vis Sci. 2009 Jun;50(6):2903-12
10812228 - Vaccine. 2000 Jun 15;18(25):2843-55
23392640 - Curr Protoc Immunol. 2013 Feb;Chapter 18:Unit 18.3.
16306600 - J Virol. 2005 Dec;79(24):15289-301
21718746 - Vaccine. 2011 Aug 11;29(35):5824-36
17114419 - J Immunol. 2006 Dec 1;177(11):7515-9
18635804 - Science. 2008 Jul 18;321(5887):408-11
21930973 - J Immunol. 2011 Oct 15;187(8):4068-76
18209024 - J Immunol. 2008 Feb 1;180(3):1309-15
16956387 - Immunol Cell Biol. 2006 Dec;84(6):543-50
17606632 - J Exp Med. 2007 Jul 9;204(7):1625-36
11062538 - Nat Med. 2000 Nov;6(11):1258-63
23485763 - Med Princ Pract. 2013;22(5):464-8
12445314 - Tissue Antigens. 2002 Jun;59(6):443-51
20124097 - J Immunol. 2010 Mar 1;184(5):2561-71
8609407 - J Immunol. 1996 Apr 15;156(8):2874-84
19129756 - Mucosal Immunol. 2009 Mar;2(2):129-43
22701511 - Future Virol. 2012 Apr 1;7(4):371-378
10980387 - Hum Immunol. 2000 Aug;61(8):764-79
18452963 - Virology. 2008 Jul 5;376(2):279-89
16912286 - J Virol. 2006 Sep;80(17):8351-61
19211753 - J Virol. 2009 Apr;83(8):3696-703
10547406 - N Engl J Med. 1999 Nov 4;341(19):1432-8
15153496 - J Immunol. 2004 Jun 1;172(11):6783-9
11136822 - J Exp Med. 2001 Jan 1;193(1):73-88
18799581 - J Virol. 2008 Dec;82(23):11792-802
10537110 - Nature. 1999 Oct 14;401(6754):708-12
23776170 - J Immunol. 2013 Jul 15;191(2):583-93
16699031 - J Virol. 2006 Jun;80(11):5509-15
19264627 - J Gen Virol. 2009 May;90(Pt 5):1153-63
15933776 - Braz J Med Biol Res. 2005 Jun;38(6):837-42
24798939 - Hum Immunol. 2014 Aug;75(8):715-29
22649204 - J Immunol. 2012 Jul 1;189(1):425-32
14580882 - J Immunol Methods. 2003 Oct 1;281(1-2):65-78
16824126 - Immunol Rev. 2006 Jun;211:164-81
23326289 - Clin Dev Immunol. 2012;2012:732546
23543059 - J Clin Invest. 2013 May;123(5):1976-87
22318137 - J Virol. 2012 Apr;86(8):4358-69
16103205 - J Virol. 2005 Sep;79(17):11523-8
22678897 - Eur J Immunol. 2012 Jun;42(6):1405-16
18097044 - J Immunol. 2008 Jan 1;180(1):426-37
20935204 - J Immunol. 2010 Nov 1;185(9):4988-92
14528297 - Nat Med. 2003 Nov;9(11):1377-82
15368273 - Eur J Immunol. 2004 Nov;34(11):3102-14
25108380 - Virology. 2014 Sep;464-465:296-311
17475646 - J Virol. 2007 Jul;81(14):7647-61
23018456 - J Immunol. 2012 Nov 1;189(9):4496-509
8125143 - Eur J Immunol. 1994 Mar;24(3):765-8
11704282 - Hum Immunol. 2001 Nov;62(11):1200-16
18523254 - J Immunol. 2008 Jun 15;180(12):7907-18
17349872 - Hum Immunol. 2007 Mar;68(3):170-80
17698591 - J Exp Med. 2007 Sep 3;204(9):2015-21
17146573 - Ocul Surf. 2006 Oct;4(4):178-87
17898288 - Invest Ophthalmol Vis Sci. 2007 Oct;48(10):4643-53
11972639 - Immunology. 2002 May;106(1):113-21
22216840 - N Engl J Med. 2012 Jan 5;366(1):34-43
11007933 - Forum (Genova). 2000 Jul-Sep;10(3):256-70
22318154 - J Virol. 2012 Apr;86(8):4328-39
Mackenzie (2023010207164153700_r64) 2014; 111
Samandary (2023010207164153700_r4) 2014; 75
Kessler (2023010207164153700_r36) 2001; 193
Chentoufi (2023010207164153700_r2) 2008; 180
Dervillez (2023010207164153700_r20) 2012; 7
Kuo (2023010207164153700_r5) 2014; 32
2023010207164153700_r54
Khan (2023010207164153700_r75) 2014; 10
Bettahi (2023010207164153700_r63) 2007; 48
Joshi (2023010207164153700_r66) 2011; 187
Zhang (2023010207164153700_r15) 2005; 79
Hertz (2023010207164153700_r52) 2007; 23
Wang (2023010207164153700_r47) 2002; 99
Cornberg (2023010207164153700_r65) 2010; 184
Chentoufi (2023010207164153700_r11) 2010; 184
Long (2023010207164153700_r7) 2014; 464-465
Benmohamed (2023010207164153700_r32) 2000; 18
BenMohamed (2023010207164153700_r58) 2002; 2
Stuber (2023010207164153700_r24) 1994; 24
Intlekofer (2023010207164153700_r30) 2008; 321
Nesburn (2023010207164153700_r59) 2007; 81
Dasgupta (2023010207164153700_r13) 2011; 29
Belshe (2023010207164153700_r17) 2012; 366
Muller (2023010207164153700_r19) 2009; 90
Rubio (2023010207164153700_r26) 2003; 9
Ladell (2023010207164153700_r39) 2008; 180
Pekiner (2023010207164153700_r71) 2013; 22
Zhang (2023010207164153700_r3) 2012; 189
Koelle (2023010207164153700_r21) 2003; 100
Chentoufi (2023010207164153700_r6) 2012; 2012
Banerjee (2023010207164153700_r42) 2010; 185
Murphy (2023010207164153700_r18) 2008; 376
Boucherma (2023010207164153700_r29) 2013; 191
Dervillez (2023010207164153700_r1) 2013; 191
Chentoufi (2023010207164153700_r14) 2008; 82
Conrady (2023010207164153700_r77) 2012; 189
Intlekofer (2023010207164153700_r43) 2007; 204
Zhu (2023010207164153700_r68) 2004; 34
Stock (2023010207164153700_r49) 2006; 84
Gilchuk (2023010207164153700_r57) 2013; 123
BenMohamed (2023010207164153700_r27) 2002; 106
McKinney (2023010207164153700_r35) 2004; 173
Wallace (2023010207164153700_r51) 1999; 73
Takemoto (2023010207164153700_r44) 2006; 177
Sallusto (2023010207164153700_r37) 1999; 401
Daubersies (2023010207164153700_r33) 2000; 6
Nesburn (2023010207164153700_r69) 2006; 4
Hüfner (2023010207164153700_r76) 2009; 83
BenMohamed (2023010207164153700_r67) 2002; 32
Hosken (2023010207164153700_r8) 2006; 80
Kalantari-Dehaghi (2023010207164153700_r10) 2012; 86
Mott (2023010207164153700_r60) 2009; 50
Oh (2023010207164153700_r23) 2004; 64
Koelle (2023010207164153700_r22) 2001; 166
Pelte (2023010207164153700_r48) 2004; 172
Storkus (2023010207164153700_r50) 2000; 10
Selin (2023010207164153700_r74) 2004; 16
Sette (2023010207164153700_r62) 2002; 59
Harndahl (2023010207164153700_r55) 2012; 42
El-Awar (2023010207164153700_r70) 2007; 68
Sidney (2023010207164153700_r61) 2001; 62
Zhang (2023010207164153700_r31) 2009; 2
Bernardin (2023010207164153700_r46) 2005; 79
BenMohamed (2023010207164153700_r28) 2000; 61
Joshi (2023010207164153700_r45) 2008; 180
Hikono (2023010207164153700_r38) 2007; 204
Betts (2023010207164153700_r25) 2003; 281
Langenberg (2023010207164153700_r12) 1999; 341
Channappanavar (2023010207164153700_r40) 2012; 7
Dasgupta (2023010207164153700_r9) 2012; 86
Botten (2023010207164153700_r53) 2006; 80
Kao (2023010207164153700_r41) 2011; 12
Stanberry (2023010207164153700_r16) 2002; 347
St Leger (2023010207164153700_r56) 2011; 186
Castelli (2023010207164153700_r72) 2005; 38
Selin (2023010207164153700_r73) 2006; 211
Bottius (2023010207164153700_r34) 1996; 156
References_xml – volume: 7
  start-page: 371
  year: 2012
  ident: 2023010207164153700_r20
  article-title: Future of an “Asymptomatic” T-cell Epitope-Based Therapeutic Herpes Simplex Vaccine.
  publication-title: Future Virol
  doi: 10.2217/fvl.12.22
  contributor:
    fullname: Dervillez
– volume: 184
  start-page: 2825
  year: 2010
  ident: 2023010207164153700_r65
  article-title: CD8 T cell cross-reactivity networks mediate heterologous immunity in human EBV and murine vaccinia virus infections.
  publication-title: J. Immunol.
  doi: 10.4049/jimmunol.0902168
  contributor:
    fullname: Cornberg
– volume: 204
  start-page: 2015
  year: 2007
  ident: 2023010207164153700_r43
  article-title: Requirement for T-bet in the aberrant differentiation of unhelped memory CD8+ T cells.
  publication-title: J. Exp. Med.
  doi: 10.1084/jem.20070841
  contributor:
    fullname: Intlekofer
– volume: 62
  start-page: 1200
  year: 2001
  ident: 2023010207164153700_r61
  article-title: Majority of peptides binding HLA-A*0201 with high affinity crossreact with other A2-supertype molecules.
  publication-title: Hum. Immunol.
  doi: 10.1016/S0198-8859(01)00319-6
  contributor:
    fullname: Sidney
– volume: 68
  start-page: 170
  year: 2007
  ident: 2023010207164153700_r70
  article-title: HLA class I epitopes: recognition of binding sites by mAbs or eluted alloantibody confirmed with single recombinant antigens.
  publication-title: Hum. Immunol.
  doi: 10.1016/j.humimm.2006.11.006
  contributor:
    fullname: El-Awar
– volume: 193
  start-page: 73
  year: 2001
  ident: 2023010207164153700_r36
  article-title: Efficient identification of novel HLA-A(*)0201-presented cytotoxic T lymphocyte epitopes in the widely expressed tumor antigen PRAME by proteasome-mediated digestion analysis.
  publication-title: J. Exp. Med.
  doi: 10.1084/jem.193.1.73
  contributor:
    fullname: Kessler
– volume: 166
  start-page: 4049
  year: 2001
  ident: 2023010207164153700_r22
  article-title: CD8 CTL from genital herpes simplex lesions: recognition of viral tegument and immediate early proteins and lysis of infected cutaneous cells.
  publication-title: J. Immunol.
  doi: 10.4049/jimmunol.166.6.4049
  contributor:
    fullname: Koelle
– volume: 24
  start-page: 765
  year: 1994
  ident: 2023010207164153700_r24
  article-title: Identification of wild-type and mutant p53 peptides binding to HLA-A2 assessed by a peptide loading-deficient cell line assay and a novel major histocompatibility complex class I peptide binding assay.
  publication-title: Eur. J. Immunol.
  doi: 10.1002/eji.1830240341
  contributor:
    fullname: Stuber
– volume: 84
  start-page: 543
  year: 2006
  ident: 2023010207164153700_r49
  article-title: CTL response compensation for the loss of an immunodominant class I-restricted HSV-1 determinant.
  publication-title: Immunol. Cell Biol.
  doi: 10.1111/j.1440-1711.2006.01469.x
  contributor:
    fullname: Stock
– volume: 10
  start-page: 256
  year: 2000
  ident: 2023010207164153700_r50
  article-title: Melanoma antigens recognised by CD8+ and CD4+ T cells.
  publication-title: Forum (Genova)
  contributor:
    fullname: Storkus
– volume: 156
  start-page: 2874
  year: 1996
  ident: 2023010207164153700_r34
  article-title: A novel Plasmodium falciparum sporozoite and liver stage antigen (SALSA) defines major B, T helper, and CTL epitopes.
  publication-title: J. Immunol.
  doi: 10.4049/jimmunol.156.8.2874
  contributor:
    fullname: Bottius
– volume: 211
  start-page: 164
  year: 2006
  ident: 2023010207164153700_r73
  article-title: Memory of mice and men: CD8+ T-cell cross-reactivity and heterologous immunity.
  publication-title: Immunol. Rev.
  doi: 10.1111/j.0105-2896.2006.00394.x
  contributor:
    fullname: Selin
– volume: 347
  start-page: 1652
  year: 2002
  ident: 2023010207164153700_r16
  article-title: Glycoprotein-D-adjuvant vaccine to prevent genital herpes.
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa011915
  contributor:
    fullname: Stanberry
– volume: 12
  start-page: 663
  year: 2011
  ident: 2023010207164153700_r41
  article-title: Transcription factor T-bet represses expression of the inhibitory receptor PD-1 and sustains virus-specific CD8+ T cell responses during chronic infection.
  publication-title: Nat. Immunol.
  doi: 10.1038/ni.2046
  contributor:
    fullname: Kao
– volume: 106
  start-page: 113
  year: 2002
  ident: 2023010207164153700_r27
  article-title: Intranasal administration of a synthetic lipopeptide without adjuvant induces systemic immune responses.
  publication-title: Immunology
  doi: 10.1046/j.1365-2567.2002.01396.x
  contributor:
    fullname: BenMohamed
– volume: 321
  start-page: 408
  year: 2008
  ident: 2023010207164153700_r30
  article-title: Anomalous type 17 response to viral infection by CD8+ T cells lacking T-bet and eomesodermin.
  publication-title: Science
  doi: 10.1126/science.1159806
  contributor:
    fullname: Intlekofer
– ident: 2023010207164153700_r54
– volume: 75
  start-page: 715
  year: 2014
  ident: 2023010207164153700_r4
  article-title: Associations of HLA-A, HLA-B and HLA-C alleles frequency with prevalence of herpes simplex virus infections and diseases across global populations: implication for the development of an universal CD8+ T-cell epitope-based vaccine.
  publication-title: Hum. Immunol.
  doi: 10.1016/j.humimm.2014.04.016
  contributor:
    fullname: Samandary
– volume: 79
  start-page: 15289
  year: 2005
  ident: 2023010207164153700_r15
  article-title: Th-cytotoxic T-lymphocyte chimeric epitopes extended by Nepsilon-palmitoyl lysines induce herpes simplex virus type 1-specific effector CD8+ Tc1 responses and protect against ocular infection.
  publication-title: J. Virol.
  doi: 10.1128/JVI.79.24.15289-15301.2005
  contributor:
    fullname: Zhang
– volume: 99
  start-page: 3360
  year: 2002
  ident: 2023010207164153700_r47
  article-title: Identification of an HLA A*0201-restricted CD8(+) T-cell epitope for the glycoprotein B homolog of human herpesvirus 8.
  publication-title: Blood
  doi: 10.1182/blood.V99.9.3360
  contributor:
    fullname: Wang
– volume: 401
  start-page: 708
  year: 1999
  ident: 2023010207164153700_r37
  article-title: Two subsets of memory T lymphocytes with distinct homing potentials and effector functions.
  publication-title: Nature
  doi: 10.1038/44385
  contributor:
    fullname: Sallusto
– volume: 29
  start-page: 5824
  year: 2011
  ident: 2023010207164153700_r13
  article-title: Of mice and not humans: how reliable are animal models for evaluation of herpes CD8(+)-T cell-epitopes-based immunotherapeutic vaccine candidates?
  publication-title: Vaccine
  doi: 10.1016/j.vaccine.2011.06.083
  contributor:
    fullname: Dasgupta
– volume: 86
  start-page: 4328
  year: 2012
  ident: 2023010207164153700_r10
  article-title: Discovery of potential diagnostic and vaccine antigens in herpes simplex virus 1 and 2 by proteome-wide antibody profiling.
  publication-title: J. Virol.
  doi: 10.1128/JVI.05194-11
  contributor:
    fullname: Kalantari-Dehaghi
– volume: 191
  start-page: 5124
  year: 2013
  ident: 2023010207164153700_r1
  article-title: Asymptomatic HLA-A*02:01-restricted epitopes from herpes simplex virus glycoprotein B preferentially recall polyfunctional CD8+ T cells from seropositive asymptomatic individuals and protect HLA transgenic mice against ocular herpes.
  publication-title: J. Immunol.
  doi: 10.4049/jimmunol.1301415
  contributor:
    fullname: Dervillez
– volume: 185
  start-page: 4988
  year: 2010
  ident: 2023010207164153700_r42
  article-title: Cutting edge: the transcription factor eomesodermin enables CD8+ T cells to compete for the memory cell niche.
  publication-title: J. Immunol.
  doi: 10.4049/jimmunol.1002042
  contributor:
    fullname: Banerjee
– volume: 4
  start-page: 178
  year: 2006
  ident: 2023010207164153700_r69
  article-title: Topical/mucosal delivery of sub-unit vaccines that stimulate the ocular mucosal immune system.
  publication-title: Ocul. Surf.
  doi: 10.1016/S1542-0124(12)70164-7
  contributor:
    fullname: Nesburn
– volume: 73
  start-page: 7619
  year: 1999
  ident: 2023010207164153700_r51
  article-title: The cytotoxic T-cell response to herpes simplex virus type 1 infection of C57BL/6 mice is almost entirely directed against a single immunodominant determinant.
  publication-title: J. Virol.
  doi: 10.1128/JVI.73.9.7619-7626.1999
  contributor:
    fullname: Wallace
– volume: 86
  start-page: 4358
  year: 2012
  ident: 2023010207164153700_r9
  article-title: Immunodominant “asymptomatic” herpes simplex virus 1 and 2 protein antigens identified by probing whole-ORFome microarrays with serum antibodies from seropositive asymptomatic versus symptomatic individuals.
  publication-title: J. Virol.
  doi: 10.1128/JVI.07107-11
  contributor:
    fullname: Dasgupta
– volume: 6
  start-page: 1258
  year: 2000
  ident: 2023010207164153700_r33
  article-title: Protection against Plasmodium falciparum malaria in chimpanzees by immunization with the conserved pre-erythrocytic liver-stage antigen 3.
  publication-title: Nat. Med.
  doi: 10.1038/81366
  contributor:
    fullname: Daubersies
– volume: 464-465
  start-page: 296
  year: 2014
  ident: 2023010207164153700_r7
  article-title: Identification of novel virus-specific antigens by CD4⁺ and CD8⁺ T cells from asymptomatic HSV-2 seropositive and seronegative donors.
  publication-title: Virology
  doi: 10.1016/j.virol.2014.07.018
  contributor:
    fullname: Long
– volume: 2
  start-page: 129
  year: 2009
  ident: 2023010207164153700_r31
  article-title: A genital tract peptide epitope vaccine targeting TLR-2 efficiently induces local and systemic CD8+ T cells and protects against herpes simplex virus type 2 challenge.
  publication-title: Mucosal Immunol.
  doi: 10.1038/mi.2008.81
  contributor:
    fullname: Zhang
– volume: 64
  start-page: 2610
  year: 2004
  ident: 2023010207164153700_r23
  article-title: Human CTLs to wild-type and enhanced epitopes of a novel prostate and breast tumor-associated protein, TARP, lyse human breast cancer cells.
  publication-title: Cancer Res.
  doi: 10.1158/0008-5472.CAN-03-2183
  contributor:
    fullname: Oh
– volume: 123
  start-page: 1976
  year: 2013
  ident: 2023010207164153700_r57
  article-title: Discovering naturally processed antigenic determinants that confer protective T cell immunity.
  publication-title: J. Clin. Invest.
  doi: 10.1172/JCI67388
  contributor:
    fullname: Gilchuk
– volume: 59
  start-page: 443
  year: 2002
  ident: 2023010207164153700_r62
  article-title: Optimizing vaccine design for cellular processing, MHC binding and TCR recognition.
  publication-title: Tissue Antigens
  doi: 10.1034/j.1399-0039.2002.590601.x
  contributor:
    fullname: Sette
– volume: 173
  start-page: 1941
  year: 2004
  ident: 2023010207164153700_r35
  article-title: Recognition of variant HIV-1 epitopes from diverse viral subtypes by vaccine-induced CTL.
  publication-title: J. Immunol.
  doi: 10.4049/jimmunol.173.3.1941
  contributor:
    fullname: McKinney
– volume: 81
  start-page: 7647
  year: 2007
  ident: 2023010207164153700_r59
  article-title: Functional Foxp3+ CD4+ CD25(Bright+) “natural” regulatory T cells are abundant in rabbit conjunctiva and suppress virus-specific CD4+ and CD8+ effector T cells during ocular herpes infection.
  publication-title: J. Virol.
  doi: 10.1128/JVI.00294-07
  contributor:
    fullname: Nesburn
– volume: 341
  start-page: 1432
  year: 1999
  ident: 2023010207164153700_r12
  article-title: A prospective study of new infections with herpes simplex virus type 1 and type 2.
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJM199911043411904
  contributor:
    fullname: Langenberg
– volume: 366
  start-page: 34
  year: 2012
  ident: 2023010207164153700_r17
  article-title: Efficacy results of a trial of a herpes simplex vaccine.
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa1103151
  contributor:
    fullname: Belshe
– volume: 50
  start-page: 2903
  year: 2009
  ident: 2023010207164153700_r60
  article-title: The role of a glycoprotein K (gK) CD8+ T-cell epitope of herpes simplex virus on virus replication and pathogenicity.
  publication-title: Invest. Ophthalmol. Vis. Sci.
  doi: 10.1167/iovs.08-2957
  contributor:
    fullname: Mott
– volume: 111
  start-page: E784
  year: 2014
  ident: 2023010207164153700_r64
  article-title: Effector and central memory T helper 2 cells respond differently to peptide immunotherapy.
  publication-title: Proc. Natl. Acad. Sci. USA
  doi: 10.1073/pnas.1316178111
  contributor:
    fullname: Mackenzie
– volume: 376
  start-page: 279
  year: 2008
  ident: 2023010207164153700_r18
  article-title: The HSV-1 tegument protein pUL46 associates with cellular membranes and viral capsids.
  publication-title: Virology
  doi: 10.1016/j.virol.2008.03.018
  contributor:
    fullname: Murphy
– volume: 83
  start-page: 3696
  year: 2009
  ident: 2023010207164153700_r76
  article-title: Fewer latent herpes simplex virus type 1 and cytotoxic T cells occur in the ophthalmic division than in the maxillary and mandibular divisions of the human trigeminal ganglion and nerve.
  publication-title: J. Virol.
  doi: 10.1128/JVI.02464-08
  contributor:
    fullname: Hüfner
– volume: 61
  start-page: 764
  year: 2000
  ident: 2023010207164153700_r28
  article-title: Induction of CTL response by a minimal epitope vaccine in HLA A*0201/DR1 transgenic mice: dependence on HLA class II restricted T(H) response.
  publication-title: Hum. Immunol.
  doi: 10.1016/S0198-8859(00)00139-7
  contributor:
    fullname: BenMohamed
– volume: 32
  start-page: 6733
  year: 2014
  ident: 2023010207164153700_r5
  article-title: The challenges and opportunities for the development of a T-cell epitope-based herpes simplex vaccine.
  publication-title: Vaccine
  doi: 10.1016/j.vaccine.2014.10.002
  contributor:
    fullname: Kuo
– volume: 204
  start-page: 1625
  year: 2007
  ident: 2023010207164153700_r38
  article-title: Activation phenotype, rather than central- or effector-memory phenotype, predicts the recall efficacy of memory CD8+ T cells.
  publication-title: J. Exp. Med.
  doi: 10.1084/jem.20070322
  contributor:
    fullname: Hikono
– volume: 22
  start-page: 464
  year: 2013
  ident: 2023010207164153700_r71
  article-title: HLA-A, B (Class I) and HLA-DR, DQ (Class II) antigens in Turkish patients with recurrent aphthous ulceration and Behçet’s disease.
  publication-title: Med. Princ. Pract.
  doi: 10.1159/000348366
  contributor:
    fullname: Pekiner
– volume: 189
  start-page: 425
  year: 2012
  ident: 2023010207164153700_r77
  article-title: CD8+ T cells suppress viral replication in the cornea but contribute to VEGF-C-induced lymphatic vessel genesis.
  publication-title: J. Immunol.
  doi: 10.4049/jimmunol.1200063
  contributor:
    fullname: Conrady
– volume: 191
  start-page: 583
  year: 2013
  ident: 2023010207164153700_r29
  article-title: HLA-A*01:03, HLA-A*24:02, HLA-B*08:01, HLA-B*27:05, HLA-B*35:01, HLA-B*44:02, and HLA-C*07:01 monochain transgenic/H-2 class I null mice: novel versatile preclinical models of human T cell responses.
  publication-title: J. Immunol.
  doi: 10.4049/jimmunol.1300483
  contributor:
    fullname: Boucherma
– volume: 42
  start-page: 1405
  year: 2012
  ident: 2023010207164153700_r55
  article-title: Peptide-MHC class I stability is a better predictor than peptide affinity of CTL immunogenicity.
  publication-title: Eur. J. Immunol.
  doi: 10.1002/eji.201141774
  contributor:
    fullname: Harndahl
– volume: 189
  start-page: 4496
  year: 2012
  ident: 2023010207164153700_r3
  article-title: Targeting the genital tract mucosa with a lipopeptide/recombinant adenovirus prime/boost vaccine induces potent and long-lasting CD8+ T cell immunity against herpes: importance of MyD88.
  publication-title: J. Immunol.
  doi: 10.4049/jimmunol.1201121
  contributor:
    fullname: Zhang
– volume: 100
  start-page: 12899
  year: 2003
  ident: 2023010207164153700_r21
  article-title: Immunodominance among herpes simplex virus-specific CD8 T cells expressing a tissue-specific homing receptor.
  publication-title: Proc. Natl. Acad. Sci. USA
  doi: 10.1073/pnas.2131705100
  contributor:
    fullname: Koelle
– volume: 2
  start-page: 425
  year: 2002
  ident: 2023010207164153700_r58
  article-title: Lipopeptide vaccines—yesterday, today, and tomorrow.
  publication-title: Lancet Infect. Dis.
  doi: 10.1016/S1473-3099(02)00318-3
  contributor:
    fullname: BenMohamed
– volume: 281
  start-page: 65
  year: 2003
  ident: 2023010207164153700_r25
  article-title: Sensitive and viable identification of antigen-specific CD8+ T cells by a flow cytometric assay for degranulation.
  publication-title: J. Immunol. Methods
  doi: 10.1016/S0022-1759(03)00265-5
  contributor:
    fullname: Betts
– volume: 180
  start-page: 426
  year: 2008
  ident: 2023010207164153700_r2
  article-title: HLA-A*0201-restricted CD8+ cytotoxic T lymphocyte epitopes identified from herpes simplex virus glycoprotein D.
  publication-title: J. Immunol.
  doi: 10.4049/jimmunol.180.1.426
  contributor:
    fullname: Chentoufi
– volume: 38
  start-page: 837
  year: 2005
  ident: 2023010207164153700_r72
  article-title: Typing class I HLA-A gene using a nested PCR-RFLP procedure.
  publication-title: Braz. J. Med. Biol. Res.
  doi: 10.1590/S0100-879X2005000600004
  contributor:
    fullname: Castelli
– volume: 80
  start-page: 5509
  year: 2006
  ident: 2023010207164153700_r8
  article-title: Diversity of the CD8+ T-cell response to herpes simplex virus type 2 proteins among persons with genital herpes.
  publication-title: J. Virol.
  doi: 10.1128/JVI.02659-05
  contributor:
    fullname: Hosken
– volume: 82
  start-page: 11792
  year: 2008
  ident: 2023010207164153700_r14
  article-title: Asymptomatic human CD4+ cytotoxic T-cell epitopes identified from herpes simplex virus glycoprotein B.
  publication-title: J. Virol.
  doi: 10.1128/JVI.00692-08
  contributor:
    fullname: Chentoufi
– volume: 186
  start-page: 3927
  year: 2011
  ident: 2023010207164153700_r56
  article-title: Defining the herpes simplex virus-specific CD8+ T cell repertoire in C57BL/6 mice.
  publication-title: J. Immunol.
  doi: 10.4049/jimmunol.1003735
  contributor:
    fullname: St Leger
– volume: 184
  start-page: 2561
  year: 2010
  ident: 2023010207164153700_r11
  article-title: A novel HLA (HLA-A*0201) transgenic rabbit model for preclinical evaluation of human CD8+ T cell epitope-based vaccines against ocular herpes.
  publication-title: J. Immunol.
  doi: 10.4049/jimmunol.0902322
  contributor:
    fullname: Chentoufi
– volume: 79
  start-page: 11523
  year: 2005
  ident: 2023010207164153700_r46
  article-title: Human immunodeficiency virus mutations during the first month of infection are preferentially found in known cytotoxic T-lymphocyte epitopes.
  publication-title: J. Virol.
  doi: 10.1128/JVI.79.17.11523-11528.2005
  contributor:
    fullname: Bernardin
– volume: 187
  start-page: 4068
  year: 2011
  ident: 2023010207164153700_r66
  article-title: Increased numbers of preexisting memory CD8 T cells and decreased T-bet expression can restrain terminal differentiation of secondary effector and memory CD8 T cells.
  publication-title: J. Immunol.
  doi: 10.4049/jimmunol.1002145
  contributor:
    fullname: Joshi
– volume: 172
  start-page: 6783
  year: 2004
  ident: 2023010207164153700_r48
  article-title: Random screening of proteins for HLA-A*0201-binding nine-amino acid peptides is not sufficient for identifying CD8 T cell epitopes recognized in the context of HLA-A*0201.
  publication-title: J. Immunol.
  doi: 10.4049/jimmunol.172.11.6783
  contributor:
    fullname: Pelte
– volume: 48
  start-page: 4643
  year: 2007
  ident: 2023010207164153700_r63
  article-title: Protective immunity against ocular herpes infection and disease induced by highly immunogenic self-adjuvanting glycoprotein D lipopeptide vaccines.
  publication-title: Invest. Ophthalmol. Vis. Sci.
  doi: 10.1167/iovs.07-0356
  contributor:
    fullname: Bettahi
– volume: 180
  start-page: 7907
  year: 2008
  ident: 2023010207164153700_r39
  article-title: Central memory CD8+ T cells appear to have a shorter lifespan and reduced abundance as a function of HIV disease progression.
  publication-title: J. Immunol.
  doi: 10.4049/jimmunol.180.12.7907
  contributor:
    fullname: Ladell
– volume: 32
  start-page: 2274
  year: 2002
  ident: 2023010207164153700_r67
  article-title: Systemic immune responses induced by mucosal administration of lipopeptides without adjuvant.
  publication-title: Eur. J. Immunol.
  doi: 10.1002/1521-4141(200208)32:8<2274::AID-IMMU2274>3.0.CO;2-C
  contributor:
    fullname: BenMohamed
– volume: 16
  start-page: 335
  year: 2004
  ident: 2023010207164153700_r74
  article-title: CD8 memory T cells: cross-reactivity and heterologous immunity.
  publication-title: Semin. Immunol.
  doi: 10.1016/j.smim.2004.08.014
  contributor:
    fullname: Selin
– volume: 10
  start-page: 945
  year: 2014
  ident: 2023010207164153700_r75
  article-title: Asymptomatic memory CD8+ T cells: from development and regulation to consideration for human vaccines and immunotherapeutics.
  publication-title: Hum. Vaccin. Immunother.
  doi: 10.4161/hv.27762
  contributor:
    fullname: Khan
– volume: 34
  start-page: 3102
  year: 2004
  ident: 2023010207164153700_r68
  article-title: Lipopeptide epitopes extended by an Nepsilon-palmitoyl-lysine moiety increase uptake and maturation of dendritic cells through a Toll-like receptor-2 pathway and trigger a Th1-dependent protective immunity.
  publication-title: Eur. J. Immunol.
  doi: 10.1002/eji.200425166
  contributor:
    fullname: Zhu
– volume: 23
  start-page: e148
  year: 2007
  ident: 2023010207164153700_r52
  article-title: Identifying HLA supertypes by learning distance functions.
  publication-title: Bioinformatics
  doi: 10.1093/Bioinformatics/btl324
  contributor:
    fullname: Hertz
– volume: 90
  start-page: 1153
  year: 2009
  ident: 2023010207164153700_r19
  article-title: Herpes simplex virus type 2 tegument proteins contain subdominant T-cell epitopes detectable in BALB/c mice after DNA immunization and infection.
  publication-title: J. Gen. Virol.
  doi: 10.1099/vir.0.008771-0
  contributor:
    fullname: Muller
– volume: 18
  start-page: 2843
  year: 2000
  ident: 2023010207164153700_r32
  article-title: High immunogenicity in chimpanzees of peptides and lipopeptides derived from four new Plasmodium falciparum pre-erythrocytic molecules.
  publication-title: Vaccine
  doi: 10.1016/S0264-410X(00)00068-2
  contributor:
    fullname: Benmohamed
– volume: 7
  start-page: e39757
  year: 2012
  ident: 2023010207164153700_r40
  article-title: Blocking of PDL-1 interaction enhances primary and secondary CD8 T cell response to herpes simplex virus-1 infection.
  publication-title: PLoS ONE
  doi: 10.1371/journal.pone.0039757
  contributor:
    fullname: Channappanavar
– volume: 177
  start-page: 7515
  year: 2006
  ident: 2023010207164153700_r44
  article-title: Cutting edge: IL-12 inversely regulates T-bet and eomesodermin expression during pathogen-induced CD8+ T cell differentiation.
  publication-title: J. Immunol.
  doi: 10.4049/jimmunol.177.11.7515
  contributor:
    fullname: Takemoto
– volume: 2012
  start-page: 732546
  year: 2012
  ident: 2023010207164153700_r6
  article-title: Immunity to ocular and genital herpes simplex viruses infections.
  publication-title: Clin. Dev. Immunol.
  contributor:
    fullname: Chentoufi
– volume: 80
  start-page: 8351
  year: 2006
  ident: 2023010207164153700_r53
  article-title: Identification of protective Lassa virus epitopes that are restricted by HLA-A2.
  publication-title: J. Virol.
  doi: 10.1128/JVI.00896-06
  contributor:
    fullname: Botten
– volume: 9
  start-page: 1377
  year: 2003
  ident: 2023010207164153700_r26
  article-title: Ex vivo identification, isolation and analysis of tumor-cytolytic T cells.
  publication-title: Nat. Med.
  doi: 10.1038/nm942
  contributor:
    fullname: Rubio
– volume: 180
  start-page: 1309
  year: 2008
  ident: 2023010207164153700_r45
  article-title: Effector CD8 T cell development: a balancing act between memory cell potential and terminal differentiation.
  publication-title: J. Immunol.
  doi: 10.4049/jimmunol.180.3.1309
  contributor:
    fullname: Joshi
SSID ssj0006024
Score 2.372113
Snippet The HSV type 1 tegument virion phosphoprotein (VP) 11/12 (VP11/12) is a major Ag targeted by CD8(+) T cells from HSV-seropositive individuals. However, whether...
The HSV type 1 tegument virion phosphoprotein (VP) 11/12 (VP11/12) is a major Ag targeted by CD8+ T cells from HSV-seropositive individuals. However, whether...
The Herpes Simplex Virus type 1 virion tegument phosphoprotein 11/12 (HSV-1 VP11/12) is a major antigen targeted by CD8 + T cells from HSV-seropositive...
SourceID pubmedcentral
proquest
crossref
pubmed
SourceType Open Access Repository
Aggregation Database
Index Database
StartPage 2232
SubjectTerms Adolescent
Adult
Aged
Algorithms
Amino Acid Sequence
Animals
Antigens, Viral - chemistry
Antigens, Viral - immunology
Asymptomatic Diseases
CD8-Positive T-Lymphocytes - immunology
CD8-Positive T-Lymphocytes - pathology
CD8-Positive T-Lymphocytes - virology
Epitopes, T-Lymphocyte - chemistry
Epitopes, T-Lymphocyte - immunology
Female
Herpes simplex virus
Herpesvirus 1, Human - chemistry
Herpesvirus 1, Human - immunology
Herpesvirus 2, Human - chemistry
Herpesvirus 2, Human - immunology
HLA-A2 Antigen - chemistry
HLA-A2 Antigen - immunology
Humans
Immunity, Cellular
Immunization
Immunologic Memory
Keratitis, Herpetic - immunology
Keratitis, Herpetic - pathology
Keratitis, Herpetic - prevention & control
Keratitis, Herpetic - virology
Male
Mice
Mice, Transgenic
Middle Aged
Molecular Sequence Data
Peptides - administration & dosage
Peptides - chemistry
Peptides - immunology
Viral Proteins - chemistry
Viral Proteins - immunology
Title HLA-A02:01-restricted epitopes identified from the herpes simplex virus tegument protein VP11/12 preferentially recall polyfunctional effector memory CD8+ T cells from seropositive asymptomatic individuals and protect humanized HLA-A02:01 transgenic mice against ocular herpes
URI https://www.ncbi.nlm.nih.gov/pubmed/25617474
https://search.proquest.com/docview/1658703879
https://search.proquest.com/docview/1808618098
https://pubmed.ncbi.nlm.nih.gov/PMC4340763
Volume 194
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3rb9MwEDfbEIgvCDYG5aVDYh9QlC1N4izhW2Gg8hhCWjftW-SkzhZpbaqkLXR_PXex8yoPAV-iKHHj2nc_3519D8ZeWkL6MQ9cUwTcMV0Ze2YQSG7GkSUlms8iLmNhjr94w1P34zk_39g8aHktLebRfnz9y7iS_6EqPkO6UpTsP1C2_ig-wHukL16Rwnj9KxoPPw_MgWVjc7TWqcgGLmqkQcoZ4nRGrlZj5QyEz-o4EiQSvSpSygv83Vim-aIw5vJiUboFlHkb0qlx9rVc4_o2ZREoYwJxKbi6Whm4QtJp9iy7WpFM1FuJyi0ky40Jee7iMnPk79lvjJFBBwOF6hynJFM-YktpiGI1mc0zlTA2raPCCp24oEweoQoIptf479sjpbIW0wInBX85SSng4UKkqOUamfKpVQNsa91N_JtKkUExMSr31F55wme19kNO8nQpUGVeKq2aasXUQulS7RYP8jRp9oBPZrQ45soayRuwnYlLtZE8FN9Ee3Olzxvvsn2pBQJH89qzvI7EUHWZNTR4e_231W7tumBy0RAjwaQHiPKJcrl57aY4g7NJyaiohaKdqIoXrSUDr15tspuU-ZGKRRx9-FSrHh5qXOosnjo8WO-OMl_rD3TVsJ9sq3UX4ZbONbrH7mqSwUBx_n22Iafb7JYqn7raZrePtWPIzo0dzSCvO0CACgjQAAGIFwGBAIpPQAMBSiBABQTQQAACwkHfhi4MQMEAujCACgagYAAIAwNGUIJAddwGAbRBAC0QAIIANAigBgE0Y4QGAkAQAA0BUBDQQ3vATt-_G70dmrrgiRk7PJibiXREIiMuE1Sq-8JO4phzPuac1Hy046xABH7AE8eKDuNo7ApH2P44EuRaIAOXO7tsa5pN5SMGwg3cxPYi6SYR3nqRLTyJP3KETxbGuMdeVfQPZyqvTdi3QmKbsGKbULNNj72oGCRE4UNzJqYyWxRhH-2XQ3KACf7Qxrd8j7IE-j32UDFV3WPFjT122GG3ugElv---maaXZRJ813Et1I0e__abT9idBtFP2dY8X8hnaEDMo-claH4AJfYpHg
link.rule.ids 230,314,780,784,885,27924,27925
linkProvider Flying Publisher
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=HLA-A02%3A01-restricted+epitopes+identified+from+the+herpes+simplex+virus+tegument+protein+VP11%2F12+preferentially+recall+polyfunctional+effector+memory+CD8%2B+T+cells+from+seropositive+asymptomatic+individuals+and+protect+humanized+HLA-A02%3A01+transgenic+mice+against+ocular+herpes&rft.jtitle=The+Journal+of+immunology+%281950%29&rft.au=Srivastava%2C+Ruchi&rft.au=Khan%2C+Arif+A&rft.au=Spencer%2C+Doran&rft.au=Vahed%2C+Hawa&rft.date=2015-03-01&rft.eissn=1550-6606&rft.volume=194&rft.issue=5&rft.spage=2232&rft_id=info:doi/10.4049%2Fjimmunol.1402606&rft_id=info%3Apmid%2F25617474&rft.externalDocID=25617474
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0022-1767&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0022-1767&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0022-1767&client=summon